Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer

Ashamalla, Hani; Zaki, Bassem I.; Mokhtar, B.; Colella, F; Selim, H.; Krishnamurthy, Muthuswamy; Ross, Paul

doi:10.1016/s0360-3016(02)03791-4

Cited by 20 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, in the current study, we conducted a phase I study, and concluded that the toxicity associated with our regimen was tolerable up to a total dose of 64.8 Gy. Our conclusions were consistent with the results of the recent phase I–II study for locally advanced pancreatic cancer, in which Ashamalla et al [18] reported that the use of hyperfractionated radiotherapy (2 fractions of 1.1 Gy each per day) to a dose of 63.8 Gy combined with weekly paclitaxel was tolerated. They also reported that good local control was observed following their regimen; complete relief of pain was achieved in 10 of 14 patients, and objective response was achieved in 5 of 17 evaluable patients.…”

Section: Discussionsupporting

confidence: 92%

Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer

Ueno¹,

Okusaka²,

Ikeda³

et al. 2004

Oncology

View full text Add to dashboard Cite

Objective: This study investigated the maximum-tolerated dose of hyperfractionated radiation therapy with protracted 5-fluorouracil (5-FU) infusion in patients with locally advanced, unresectable pancreatic cancer. Methods: Five cohorts of patients were scheduled to receive escalating doses of hyperfractionated radiation therapy (range, 45.6–64.8 Gy). All patients received two fractions of 1.2 Gy each (separated by 6 h) per day for 5 days a week, and received protracted 5-FU infusion (200 mg/m²/day) during the radiation course. The maximum-tolerated dose was defined as one dose level below the dose at which more than one third of 3–6 patients experienced dose-limiting toxicity. Results: Twenty-nine patients were enrolled in this study. The most common toxicities were nausea/vomiting and anorexia. Although 1 patient developed bleeding from a gastric ulcer 3 months after the completion of chemoradiotherapy, the maximum-tolerated dose was not reached even at the highest dose level (level 5, 64.8 Gy). The median survival time was 12.2 months and the 1-year survival rate was 55.0%. Conclusion: The toxicity associated with our regimen was tolerable up to dose level 5 (64.8 Gy). We are currently conducting a phase II study of this hyperfractionated radiation therapy with protracted 5-FU infusion at a dose of 64.8 Gy.

show abstract

Section: Discussionsupporting

confidence: 92%

Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer

Ueno¹,

Okusaka²,

Ikeda³

et al. 2004

Oncology

View full text Add to dashboard Cite

show abstract

“…Abbreviations: GOT = glutamic oxaloacetic transaminase; GPT = glutamic pyruvic transaminase. as modified radiotherapy approaches such as hyperfractionated (24) or intensity-modulated radiation therapy (25) have been conducted. Especially, gemcitabine-based chemoradiotherapy has been investigated in many studies because this agent has shown significant survival benefit compared with 5-FU in patients with metastatic pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Phase II Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer

Sudo

Yamaguchi

Ishihara

et al. 2011

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…In a phase I trial reported by Ashamalla et al, 36 patients with locally advanced pancreatic cancer were treated with hyperfractionated radiotherapy at a total dose of 63.8 Gy in 1.1-Gy fractions over 6 weeks concurrently combined with weekly paclitaxel. The MTD of paclitaxel was 60 mg/m 2 in this situation, and complete response of the tumor was seen in 2 of 17 assessable patients.…”

Section: Taxane-based Chemoradiotherapymentioning

confidence: 99%

Chemoradiotherapy for pancreatic cancer: current status and perspectives

Oya

2004

Int J Clin Oncol

View full text Add to dashboard Cite

The poor prognosis of pancreatic cancer is due to both its metastasis-prone and locally resistant nature. To improve therapeutic outcome, a multimodality approach is necessary. Chemoradiotherapy has been regarded as one of the standard treatment options, particularly for locally advanced pancreatic cancer. A number of clinical studies have been undertaken to establish the use of chemoradiotherapy, with or without surgical resection. This review systematically summarizes the current status, controversies, and prospects of postoperative, definitive, and preoperative chemoradiotherapy for pancreatic cancer.

show abstract

Hyperfractionated radiotherapy and paclitaxel for locally advanced/unresectable pancreatic cancer

Cited by 20 publications

References 18 publications

Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer

Phase I Study of Hyperfractionated Radiation Therapy with Protracted 5-Fluorouracil Infusion in Patients with Locally Advanced Pancreatic Cancer

Phase II Study of Oral S-1 and Concurrent Radiotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer

Chemoradiotherapy for pancreatic cancer: current status and perspectives

Contact Info

Product

Resources

About